Reopening Hatch-Waxman Is Decision For Congress, Not FDA, CDER’s Woodcock Says
Executive Summary
Responding to a lawmaker’s question on whether the incentives in Hatch-Waxman strike the appropriate balance, Center for Drug Evaluation and Research Director Janet Woodcock says the issue “is beyond my purview.”